Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Elda Righi et al.|JAMA|2018Cited by 761
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definitionPatrick N. A. Harris, David L. Paterson, John F. McNamara et al.|Clinical Microbiology and Infection|2016Cited by 83
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27Patrick N. A. Harris, Tony M. Korman, Nouri L. Ben Zakour et al.|Journal of Antimicrobial Chemotherapy|2017Cited by 82
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N. A. Harris, David L. Paterson, Anton Y. Peleg et al.|Trials|2015Cited by 73